141.1 ð é«åžçç
141.1.0.1 ð äžé éé»
- æµè¡ç åž (US 2023-24): STIs at record highs â Chlamydia > Gonorrhea > Syphilis > HIV
- STI çå矀åé¡:
- Urethritis / cervicitis: GC, Chlamydia, M. genitalium, Trichomonas
- Genital ulcer: HSV (#1), syphilis (#2), chancroid, LGV
- PID: GC, Chlamydia, polymicrobial
- Vaginitis: Candida, BV, Trichomonas
- Genital warts: HPV
- Systemic: HIV, syphilis, HBV, HCV, mpox
- Empirical æ²»ç for symptomatic (donât wait for results):
- Urethritis/Cervicitis: Ceftriaxone 500 mg IM + Doxycycline 100 mg BID Ã 7 d (covers GC + Chlamydia)
- PID: Ceftriaxone 500 IM + Doxycycline 100 PO Ã 14 d + Metronidazole 500 BID Ã 14 d
- Screening (CDC 2024):
- Sexually active women < 25: annual Chlamydia + GC
- MSM: annual / q3-6 mo (depending risk)
- HIV +: annual + at HIV diagnosis
- Pregnant: HIV, HBV, HCV, syphilis, GC, Chlamydia (1st trim, repeat 3rd if risk)
141.1.0.2 1ïžâ£ Major Pathogens â Quick Reference
| ç å | çå矀 | æ²»ç |
|---|---|---|
| N. gonorrhoeae | Urethritis, cervicitis, PID, DGI, conjunctivitis | Ceftriaxone 500 mg IM Ã 1 + Doxy 100 BID Ã 7d |
| C. trachomatis | Urethritis, cervicitis, PID, LGV | Doxycycline 100 BID à 7 d (preferred 2021); Azithro 1g à 1 alt |
| Treponema pallidum | Syphilis: 1° chancre / 2° rash / 3° gummas / neuro | Penicillin G IM (1°, 2°, early latent: single dose 2.4 MU; late: 3 weekly; neuro: IV à 14 d) |
| HSV 1/2 | Genital ulcer (painful, vesicular, recurrent) | Acyclovir / Valacyclovir / Famciclovir |
| HPV | Warts, cervical / anal cancer | Cryotherapy / TCA / podophyllin; vaccine é é² |
| Trichomonas vaginalis | Vaginitis (女) / urethritis (ç·) | Metronidazole 2g single OR 500 BID à 7 d |
| M. genitalium | Urethritis / cervicitis (NGU) | Doxy 7d â Azithro 4d (sequential) or Moxifloxacin if resistance |
| Haemophilus ducreyi | Chancroid (painful ulcer + adenopathy) | Azithromycin 1g single |
| Mpox | Anogenital lesions, lymphadenopathy | Supportive + tecovirimat (severe) |
| HIV | (See Ch HIV) | ART (TAF/FTC + DTG-based) |
141.1.0.3 2ïžâ£ Genital Ulcer Differential
| ç å | çŒç | éç·£ | æ·å·Žè « |
|---|---|---|---|
| HSV | +++ painful | Vesicular cluster | Mild bilateral tender |
| Syphilis 1° | Painless | Indurated, clean base | Painless, non-tender |
| Chancroid (H. ducreyi) | Painful | Ragged, purulent | Painful, suppurative buboes |
| LGV (Chlamydia L1-L3) | Painless (early) | Small, transient | Tender, âgroove signâ |
| Granuloma inguinale | Painless | Beefy red, friable | None |
| Behçetâs (not STI) | Painful | Aphthous | Variable |
141.1.0.4 3ïžâ£ Urethritis / Cervicitis
141.1.0.4.1 Etiology
- N. gonorrhoeae
- C. trachomatis (60-70% of NGU non-gonococcal urethritis)
- M. genitalium (15-25% of NGU)
- Trichomonas, HSV, adenovirus
141.1.0.4.2 Diagnosis
- NAAT (PCR) for GC + Chlamydia (urine 1st-catch or urethral / cervical / pharyngeal / rectal swab)
- M. genitalium NAAT for persistent NGU
- Gram stain urethral discharge (Gram - intracellular diplococci = GC)
141.1.0.4.3 Treatment (CDC 2021)
- Gonorrhea: Ceftriaxone 500 mg IM Ã 1 (was 250; doubled 2020 for resistance) + Doxy 100 BID Ã 7 d if Chlamydia not ruled out
- Chlamydia: Doxycycline 100 mg BID Ã 7 d (preferred 2021; replaces azithro 1g single)
- M. genitalium: doxy 7d â azithro 4d sequential OR moxifloxacin (resistance)
141.1.0.5 4ïžâ£ Syphilis (Treponema pallidum)
141.1.0.5.1 Stages
| Stage | Time | Features |
|---|---|---|
| Primary | 3 wks-3 mo | Chancre (painless ulcer); regional adenopathy |
| Secondary | 4-10 wks | Rash (palms + soles), condyloma lata, mucous patches, generalized adenopathy |
| Latent | Months-years | Asymptomatic; early latent < 1 yr, late latent > 1 yr |
| Tertiary | 5-30 yrs | Gummas, neurosyphilis, cardiovascular (aortitis) |
141.1.0.5.2 Diagnosis
- Treponemal test (FTA-ABS, TP-PA, EIA): first positive forever
- Non-treponemal (RPR, VDRL): titer follow-up; converts to negative with treatment
- Reverse algorithm (now standard): treponemal screen â non-treponemal confirm + titer
- LP for neuro: CSF VDRL, FTA-ABS, lymphocytic pleocytosis, protein â
141.1.0.5.3 Treatment
| Stage | Treatment |
|---|---|
| Primary / Secondary / Early latent | Benzathine penicillin G 2.4 MU IM single |
| Late latent / Latent unknown duration / Tertiary (non-CNS) | Benzathine PCN 2.4 MU IM weekly à 3 |
| Neurosyphilis / Ocular / Otosyphilis | Aqueous PCN G 18-24 MU IV daily à 10-14 d |
| PCN allergy (non-pregnant) | Doxycycline 100 BID Ã 14 d (early); Ã 28 d (late) |
| PCN allergy pregnant | Desensitize + PCN (no alternative for fetal protection) |
141.1.0.6 5ïžâ£ HSV (Genital Herpes)
141.1.0.6.1 Clinical
- HSV-2 (more genital), HSV-1 rising (oral-genital)
- Primary: severe; multiple painful vesicles; fever; adenopathy
- Recurrent: milder, less frequent
- Asymptomatic shedding: å€ transmission source
141.1.0.6.2 Treatment
| æ å¢ | Regimen |
|---|---|
| Primary (first episode) | Acyclovir 400 TID Ã 7-10 d OR Valacyclovir 1g BID Ã 7-10 d OR Famciclovir 250 TID Ã 7-10 d |
| Recurrent | Acyclovir 800 TID Ã 2 d OR Valacyclovir 500 BID Ã 3 d (episodic) |
| Suppression (frequent recurrences) | Daily Valacyclovir 500 daily OR Acyclovir 400 BID |
| Pregnant (from 36 wks) | Acyclovir suppression to reduce shedding at delivery |